Quest Pharmatech (QPT.V) Action Cours

Quest PharmaTech, Inc. is a biotechnology company, which develops and commercializes antibody based immunotherapeutic products for cancer. The company is headquartered in Edmonton, Alberta. The firm is developing products to improve the quality of life. The company is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The firm has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.’s technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The firm also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.